Literature DB >> 34856378

Prevalence and outcomes of concomitant cardiac amyloidosis and aortic stenosis: A systematic review and meta-analysis.

Jamie Sin-Ying Ho1, Qianyi Kor2, William Kf Kong3, Yoke Ching Lim4, Mark Yan-Yee Chan3, Nicholas Lx Syn2, Jinghao Nicholas Ngiam5, Nicholas Ws Chew4, Tiong-Cheng Yeo3, Ping Chai3, Kian-Keong Poh3, Raymond Cc Wong3, Weiqin Lin3, Ching-Hui Sia6.   

Abstract

OBJECTIVE: Cardiac amyloidosis (CA) is an increasingly recognised condition in patients with aortic stenosis (AS). However, there is a large variation in the reported prevalence figures, due to differences in populations and diagnostic methods. We aimed to investigate the prevalence, risk factors and outcomes of concomitant CA and AS.
METHODS: We performed a systematic review and meta-analysis of the literature searched on MEDLINE, Embase, Scopus and CENTRAL. We analysed the prevalence of CA in patients with AS grouped according to the diagnostic techniques, and the risk factors and outcomes of concomitant CA and AS were analysed in AS patients referred for surgical or transcatheter aortic valve replacement (AVR).
RESULTS: A total of 21 studies were included, involving 4,243 patients. The pooled prevalence of CA in patients with AS was 14.4%, with substantial heterogeneity. The pooled prevalence of AS in patients CA was 8.7%, with substantial heterogeneity. Patients with both AS and CA had higher all-cause mortality than those with AS or CA alone. In AS patients requiring AVR, CA was associated with increasing age, male sex, higher NT-proBNP levels, increased interventricular septal end diastole (IVSd) thickness and lower left ventricular ejection fraction. Concomitant AS and CA was associated with increased all-cause mortality and pacemaker implantation post-procedure. Study limitations included heterogeneity of the results and the fair to good quality of the studies published.
CONCLUSION: Overall, a substantial proportion of patients with AS may have CA, and they have poorer prognosis. A high degree of clinical suspicion is needed to identify the "red flags" and perform appropriate diagnostic imaging.
Copyright © 2021 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  amyloidosis; aortic stenosis; outcomes; prevalence; transcatheter aortic valve replacement

Mesh:

Year:  2021        PMID: 34856378     DOI: 10.1016/j.hjc.2021.11.001

Source DB:  PubMed          Journal:  Hellenic J Cardiol        ISSN: 1109-9666


  2 in total

1.  Red Flags, Prognostic Impact, and Management of Patients With Cardiac Amyloidosis and Aortic Valve Stenosis: A Systematic Review and Meta-Analysis.

Authors:  Veronika A Myasoedova; Maddalena Conte; Vincenza Valerio; Donato Moschetta; Ilaria Massaiu; Laura Petraglia; Dario Leosco; Paolo Poggio; Valentina Parisi
Journal:  Front Med (Lausanne)       Date:  2022-03-09

2.  Reply: Dual Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Do We Have Enough Evidence?

Authors:  Aayush Kumar Singal; Avinainder Singh; Raghav Bansal; Sundeep Mishra
Journal:  JACC CardioOncol       Date:  2022-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.